摘要
目的比较分析多种耐药相关基因蛋白在乳腺癌和三阴乳腺癌表达差别,进一步了解三阴乳腺癌的耐药特性,为临床治疗三阴乳腺癌选择化疗方案提供依据。方法选取术前未行化疗及内分泌治疗的的62例乳腺癌标本,其中三阴乳腺癌病例20例。采用免疫组化方法检测LRP、p170、谷胱甘肽S转移酶(GSTπ)、TopoⅡa在乳腺癌、三阴乳腺癌、非三阴乳腺癌中表达差别。结果 p170、LRP、GSTπ、TopoⅡa四种耐药基因相关蛋白在所有乳腺癌病例中阳性表达率分别为41.94%,59.68%,56.45%,62.90%,p170、LRP、GSTπ、TopoⅡa在非三阴组与三阴组阳性表达率分别为和40.48%,59.52%,47.62%,57.14%和45.00%,60.00%,75.00%,75.00%,其中GSTπ在2组中的表达差异有统计意义(P<0.05)。2组乳腺癌中多基因共表达率分别为40.00%、11.90%,差异有统计学意义(P<0.05)。结论初治乳腺癌中存在多个耐药基因蛋白表达及共表达,三阴乳腺癌比非三阴乳腺癌化疗耐药性强,化疗效果不如非三阴组敏感。GSTπ表达强于非三阴组,提示三阴乳腺癌预后较差,化疗不敏感。
Objective To investigate the different expression of several different types of drug resistance associated protein between breast carcinoma and triple negative breast carcinoma, and to explore the characteristics of drug resistance protein of triple negative breast carcinoma. Methods The expressions of drug resistance associated protein pl70, LRP, GSTπ ,Topo Ⅱ a were detected in 62 cases of breast carcinoma without chemotherapy and endocrine therapy, including 20 cases of triple breast carcinoma and 40 cases of non-triple breast carcinoma by immunochemistry. Results The positive rates of p170, LRP, GSTπTopo Ⅱ a in 62 cases of breast carcinoma were 41.94% ,59.68%, 56.45%, 62.90% respectively, which in non-triple negative breast carcinoma group were 40.48% ,59.52%, 47.62% ,57.14% respectively,and the positive rate in triple negative breast carcinoma group were 45.00% ,60.00% ,75.00% ,75.00% respectively. The positive expression of GSTπ in triple negative breast carcinoma group was significantly higher than that in non-triple negative breast carcinoma group （ P 〈 0.05 ）. The co-expression of drug resistance protein in triple negative breast carcinoma group was significantly higher than that in non-triple negative breast carcinoma group （ P 〈 0.05 ）. Conclusion The expression and co-expression of drug-resistance protein exist in initial-treated breast carcinoma. Chemotherapy may be less sensitive to triple breast carcinoma. The higher expression of GSTπ in triple breast carcinoma may imply poorer outcome of triple breast carcinoma.
出处
《河北医药》
CAS
2010年第22期3128-3130,共3页
Hebei Medical Journal
